Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12608000024347
ACTRN12608000024347
Completed
Phase 2

To investigate the pharmacokinetics and pharmacodynamics of orally administered methadone-naloxone in a 50:1 ratio in partcipants who are opioid dependant and methadone maintained individuals aged between 18- 65

angton Centre0 sites10 target enrollmentJanuary 17, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
angton Centre
Enrollment
10
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 17, 2008
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
angton Centre

Eligibility Criteria

Inclusion Criteria

  • •Opioid dependent clients;
  • •In treatment for greater than 2months
  • •Stabilised on current dose for greater than 4 weeks
  • •Willing to remain on current dose for duration of the trial
  • •Venous access
  • •Able to provide voluntary informed consent

Exclusion Criteria

  • •Considered unwilling, unable or unlikely to comply with the study protocol
  • •Lactating and pregnant women
  • •Active psychotic illness

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Clinical study to investigate the pharmacokinetics, efficacy, safety and immunogenicity of human-cl rhFVIII in previously treated patients with severe haemophilia ASevere haemophilia AHaematological DisordersHereditary factor VIII deficiency
ISRCTN87293301Octapharma AG (Switzerland)20
Active, not recruiting
Phase 1
Study to Investigate the product Wilate in Patients with Severe Hemophilia ASevere hemophilia A (<1% FVIII:C)MedDRA version: 20.0Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-003681-34-PLOctapharma AG55
Active, not recruiting
Phase 1
Study to Investigate the product Wilate in Patients with Severe Hemophilia ASevere hemophilia A (<1% FVIII:C)MedDRA version: 20.0Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-003681-34-BGOctapharma AG55
Active, not recruiting
Phase 1
Study to Investigate the product Wilate in Patients with Severe Hemophilia ASevere hemophilia A (<1% FVIII:C)MedDRA version: 19.1Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-003681-34-HUOctapharma AG55
Active, not recruiting
Not Applicable
To determine the pharmacokinetics of human-cl rhFVIII in terms of the FVIII coagulant activity (FVIII:C) and to compare it with the licensed FVIII concentrate Kogenate/Helixate in previously treated subjects suffering from severe hemophilia A.
EUCTR2008-001563-11-BGOctapharma AG22